CME Group (NASDAQ:CME) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

CME Group (NASDAQ:CME) had its price target lifted by research analysts at JPMorgan Chase & Co. from $256.00 to $262.00 in a research report issued to clients and investors on Thursday,MarketScreener reports. The brokerage presently has an “underweight” rating on the financial services provider’s stock. JPMorgan Chase & Co.‘s price objective indicates a potential downside of 7.33% from the company’s current price.

Other equities analysts have also recently issued research reports about the company. Deutsche Bank Aktiengesellschaft lifted their price target on CME Group from $310.00 to $318.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Rothschild & Co Redburn lifted their target price on CME Group from $297.00 to $300.00 and gave the stock a “neutral” rating in a research note on Thursday, November 6th. Piper Sandler boosted their target price on CME Group from $296.00 to $313.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Barclays raised their price target on CME Group from $280.00 to $304.00 and gave the company an “equal weight” rating in a report on Friday, December 12th. Finally, Royal Bank Of Canada upped their price objective on shares of CME Group from $282.00 to $295.00 and gave the company a “sector perform” rating in a report on Friday, December 5th. Nine analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, CME Group currently has a consensus rating of “Hold” and an average price target of $292.18.

CME Group Price Performance

Shares of NASDAQ CME opened at $282.73 on Thursday. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.02 and a quick ratio of 1.02. The business has a 50-day moving average of $274.17 and a 200-day moving average of $271.97. The stock has a market capitalization of $101.95 billion, a price-to-earnings ratio of 27.40, a PEG ratio of 3.16 and a beta of 0.27. CME Group has a fifty-two week low of $232.32 and a fifty-two week high of $290.79.

CME Group (NASDAQ:CME) last posted its quarterly earnings results on Wednesday, October 22nd. The financial services provider reported $2.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.05. CME Group had a net margin of 58.84% and a return on equity of 14.61%. The firm had revenue of $1.54 billion for the quarter, compared to analyst estimates of $1.56 billion. During the same period in the prior year, the firm posted $2.68 earnings per share. The company’s quarterly revenue was down 3.0% compared to the same quarter last year. As a group, sell-side analysts predict that CME Group will post 10.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In other CME Group news, Director William R. Shepard bought 251 shares of the stock in a transaction dated Tuesday, December 30th. The shares were bought at an average cost of $278.37 per share, with a total value of $69,870.87. Following the completion of the acquisition, the director owned 258,710 shares of the company’s stock, valued at $72,017,102.70. This trade represents a 0.10% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Terrence A. Duffy sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $269.55, for a total value of $6,738,750.00. Following the completion of the sale, the chief executive officer owned 65,804 shares of the company’s stock, valued at approximately $17,737,468.20. This trade represents a 27.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Amundi boosted its stake in shares of CME Group by 24.0% during the second quarter. Amundi now owns 1,987,347 shares of the financial services provider’s stock valued at $548,150,000 after purchasing an additional 385,225 shares in the last quarter. Alley Investment Management Company LLC raised its holdings in CME Group by 86.0% in the 3rd quarter. Alley Investment Management Company LLC now owns 29,223 shares of the financial services provider’s stock valued at $7,896,000 after buying an additional 13,512 shares during the last quarter. Elevate Capital Advisors LLC boosted its position in CME Group by 85.2% during the 3rd quarter. Elevate Capital Advisors LLC now owns 8,519 shares of the financial services provider’s stock worth $2,302,000 after buying an additional 3,919 shares during the period. Victory Financial Group LLC boosted its position in CME Group by 310.2% during the 2nd quarter. Victory Financial Group LLC now owns 3,044 shares of the financial services provider’s stock worth $839,000 after buying an additional 2,302 shares during the period. Finally, Chicago Capital LLC grew its holdings in CME Group by 583.8% during the 3rd quarter. Chicago Capital LLC now owns 13,327 shares of the financial services provider’s stock worth $3,601,000 after acquiring an additional 11,378 shares during the last quarter. 87.75% of the stock is owned by institutional investors.

About CME Group

CME Group Inc is a global markets company that operates some of the world’s largest and most liquid derivatives exchanges, including the Chicago Mercantile Exchange (CME), the Chicago Board of Trade (CBOT), the New York Mercantile Exchange (NYMEX) and COMEX. The firm offers futures and options contracts across a broad range of asset classes — including interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals — and serves a diverse client base of institutional investors, commercial hedgers, brokers and retail participants.

The company’s core services include electronic trading on the CME Globex platform, central clearing through CME Clearing, and distribution of market data, indexes and analytics.